Iron Pathophysiology in Parkinson Diseases.

Area of Science:

• Neuroscience
• Molecular Biology
• Pathology

Background:

• Parkinson's disease (PD) involves selective degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc).
• Iron deposits are observed in the SNpc of PD patients and animal models, indicating a role for disturbed iron metabolism.

Purpose of the Study:

• To explore the molecular mechanisms linking iron dysregulation to Parkinson's disease pathogenesis.
• To investigate the potential of iron chelation as a therapeutic strategy for PD.

Main Methods:

• Review of existing evidence on iron metabolism, ion channels, N-methyl-D-aspartate receptors, and alpha-synuclein in PD.
• Examination of the role of glial cells in iron deposition and PD pathology.
• Evaluation of iron chelators, particularly those derived from natural food sources.

Main Results:

• Dysregulation of iron transporters, L-type voltage-gated calcium channels (LTCC), ATP-sensitive potassium (KATP) channels, and N-methyl-D-aspartate receptors (NMDARs) are implicated in PD.
• Iron modulates alpha-synuclein synthesis, post-translational modification, and aggregation, a key pathological hallmark of PD.
• Activated glia, including astroglia and microglia, contribute to iron deposition in PD.

Conclusions:

• Iron chelation, especially using natural food-derived chelators, presents a promising therapeutic avenue for the prevention and treatment of Parkinson's disease.
• Targeting iron metabolism and its interplay with alpha-synuclein and glial cells could offer novel strategies for PD management.